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Abstract 
Isothermal nucleic acid amplification methods can potentially shorten the amount of time 
required to diagnose influenza. We developed and evaluated a novel isothermal nucleic acid 
amplification method, RT-SIBA to rapidly detect and differentiate between influenza A and B 
viruses in a single reaction tube. The performance of the RT-SIBA Influenza assay was 
compared with two established RT-PCR methods. The sensitivities of the RT-SIBA, RealStar 
RT-PCR, and CDC RT-PCR assays for the detection of influenza A and B viruses in the 
clinical specimens were 98.8%, 100%, and 89.3%, respectively. All three assays 
demonstrated a specificity of 100%. The average time to positive result was significantly 
shorter with the RT-SIBA Influenza assay (<20 min) than with the two RT-PCR assays (> 90 
min). The method can be run using battery-operated, portable devices with a small footprint 
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A. Introduction 
Influenza viruses are a leading cause of acute respiratory infection and represent a 
considerable public health burden worldwide (1, 2). Humans are commonly infected by 
influenza A (H1N1 and H3N2 subtypes) and B viruses, which often co-circulate during 
epidemics. Vaccination against influenza viruses is one of the most effective strategies to 
minimize the risk of infection. Seasonal influenza vaccines are recommended for young 
children and the elderly because these groups are at high risk of influenza virus infection and 
its associated complications (3). Despite seasonal vaccination, influenza virus infection 
remains associated with high morbidity and mortality rates (4). This is due to continuous 
antigenic changes in the surface glycoproteins of influenza virus strains, which reduce the 
effectiveness of vaccination (5, 6).  
 
Antiviral drugs can be used to treat patients with severe influenza virus infection. However, 
these drugs are only effective when started within the first 48 h of the illness (7). 
Consequently, effective use of antiviral drugs for the treatment of influenza virus infection 
relies on early and accurate diagnosis. Furthermore, the signs and clinical symptoms of 
influenza virus infection are similar to those of infections with other bacterial respiratory 
pathogens. Consequently, clinicians rely on in vitro diagnostic methods to confirm influenza 
virus infection. Therefore, early and accurate diagnosis is not only important for managing 
the infection but also for minimizing the unnecessary prescription of antibiotics (8, 9).  
 
Several diagnostic methods are available to detect influenza viruses in patient specimens 
(10). These include viral culture, direct fluorescent antibody (DFA) tests, serological assays, 
rapid influenza diagnostic tests (RIDTs), and nucleic acid amplification tests (NAATs). Viral 
culture is laborious and time-consuming. Although DFA tests, RIDTs, and serology assays 
have shorter turnaround times (TATs), they lack the required sensitivity (11). NAATs are 
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method to diagnose influenza due to their improved sensitivity. However, most of these 
NAATs can only be performed at central laboratory centers due to their complexity and the 
requirement for sophisticated instrumentation. Isothermal-based NAATs can potentially 
shorten the amount of time required to diagnose influenza and avoid the need for complex 
instrumentation. Consequently, these assays could be potentially used for near-patient 
testing and in low-resource settings. An influenza diagnostic test must be able to detect and 
differentiate between influenza A and B viruses because antiviral drugs have different 
efficacies against these viruses (12). However, only a limited number of isothermal-based 
NAATs can be performed in a multiplex format in a single reaction tube due to the risk of 
non-specific amplification (13-15).  
 
In this study, we developed a highly sensitive and specific multiplex assay to detect influenza 
A and B viruses called Reverse Transcription Strand Invasion-Based Amplification (RT-
SIBA). Strand invasion-based amplification (SIBA) is an isothermal method that relies on a 
recombinase-coated single-stranded invasion oligonucleotide (IO) and a polymerase for the 
rapid and exponential amplification of nucleic acids (16). SIBA is an attractive nucleic acid 
amplification method owing to its short TAT and high analytical sensitivity and specificity (17-
20). We took full advantage of these characteristics to develop a multiplex test that can 
detect and differentiate between influenza A and B viruses in a single reaction tube. 
Furthermore, the clinical performance of the multiplex RT-SIBA Influenza assay was 
compared with those of two established NAATs for the detection of influenza A and B 
viruses. 
B. Materials and methods 
  
B.1. Viral isolates and clinical specimens 
Purified and quantified viral particles from influenza A H1N1 (American Type Culture 
Collection (ATCC) VR-95PQ), influenza A H3N2 (ATCC VR-544PQ), and influenza B (ATCC 
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used to determine the limit of detection of the RT-SIBA Influenza assay. Sixteen non-
respiratory pathogens were used to evaluate the specificity of this assay. A total of 132 
retrospective nasopharyngeal (NP) swab and aspirate specimens were used to evaluate the 
three assays. Seventy-one NP swab specimens were obtained from the Discovery Life 
Sciences Biobank (Discovery Life Sciences, USA). These specimens had been previously 
determined to be positive (n = 44) or negative (n = 27) for influenza viruses using the eSensor 
Respiratory Viral Panel (GenMark Diagnostics, USA) or the Simplexa™ Flu A/B & RSV 
Direct Kit (DiaSorin, Italy). Sixty-one aspirate specimens were obtained from Karolinska 
University Hospital (Sweden). These specimens had been previously determined to be 
positive (n=40) or negative (n=21) for influenza viruses using the Simplexa™ Flu A/B & RSV 
Direct Kit (Diasorin, Italy). All specimens were used in accordance with Karolinska Institutet 
ethical Review Act 2003 and Discovery Life Sciences Biobank Bioethics Policy. 
 
B.2. Extraction and preparation of viral RNA 
 
Viral RNA was extracted from the ATCC viral particles and clinical specimens using the 
QIAamp Viral RNA Mini Kit (Qiagen, Germany). Bacterial DNA was extracted using the 
QiAmp DNA Mini kit (Qiagen). Both types of extraction were performed according to the 
manufacturer’s instructions. The quantitative genome copy numbers and infectious titers of 
the ATCC viral particles reported by the manufacturer were used to estimate the viral loads 
(Chicken Embryo Infectious Dose, CEID50) and the amount of viral RNA per reaction. RNA 
extracted from the clinical specimens was used to evaluate the clinical performance of the 
RT-SIBA Influenza assay in comparison with those of the RT-PCR assays for detecting 
influenza A and B viruses. 
 
B.3.  Multiplex RT-SIBA Influenza assay 
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The multiplex RT-SIBA Influenza assay was designed to simultaneously detect all subtypes 
of influenza A and B viruses in one reaction tube. The sequences of the influenza strains, 
which were retrieved from the Virus Pathogen Resource and the National Center for 
Biotechnology Information database, were aligned (21).  A total of 4575 non-duplicate 
influenza A segment 1 and 1495 non-duplicate influenza B segment 3 sequences were 
aligned. Influenza A assay was designed to detect the highly conserved of segment 1 to 
allow for the detection of influenza A H1N1 and H3N2 as well as pandemic strains. Likewise 
influenza B assay was designed to detect the highly conserve reqion of segment 3 to allow 
for the detection of both influenza B Yamagata and Victoria linages. Separate reaction sets 
comprising a forward primer, a reverse primer, an IO, and a locked nucleic acid (LNA) 
fluorescent probe were designed to amplify and differentiate between the RNA target regions 
of influenza A and B viruses. The dual LNA probes were used for detecting and 
distinguishing influenza A and influenza B multiplex reaction. The influenza A probe was 
labeled with ROX and Iowa black FQ quencher, whereas the influenza B probe was labeled 
with Cy5 and Iowa black RQ quencher. The sequences of the oligonucleotides used for the 
RT-SIBA Influenza assay are listed in Table 1. 
 
B.3.2. Reaction conditions 
The multiplex RT-SIBA Influenza assay was performed using the SIBA® reagent kit (Orion 
Diagnostica Oy, Finland) with the reaction supplemented with 16 units of GoScript™ 
Reverse Transcriptase (Promega, UK). The forward primer, reverse primer, IO, and probe 
were used at concentrations of 300, 200, 300, and 150 nM, respectively, to detect influenza 
A virus and at concentrations of 250, 175, 200, and 150 nM, respectively, to detect influenza 
B virus. The UvsX and Gp32 enzymes were used at concentrations of 400 and 300 ng/ml, 
respectively. A total of 2 μl of each RNA extract was used in a total reaction volume of 20 μl. 
Products were detected using fluorophore-labeled probes and SYBR Green (1:100,000 
dilution). Reactions were incubated at 43°C for 45 min, and fluorescence was measured 
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melting curve was generated after amplification at 40–95°C to verify the specificity of the 
reaction products. 
 
B.4. Multiplex reverse transcription polymerase chain reaction (RT-PCR) influenza 
assays 
 
One previously published and one commercially available a CE-certified RT-PCR assay to 
detect influenza A and B viruses were performed for comparison. The previously published 
RT-PCR assay was performed using CDC influenza A and B-specific primers and probes 
labeled with the 6-carboxyfluorescein and 4’,5’-dichloro-2’,7-dimethoxyfluorescein dyes (22). 
Each reaction (total volume of 20 µl) contained 10 µl 2× EXPRESS qPCR Supermix, 
Universal (Thermo Fisher Scientific, Finland), 2 µl Express SuperScript® Mix for One-Step 
qPCR (Thermo Fisher Scientific), 1 µM of each primer, 0.04 µM probes, and 2 µl RNA 
extract. The reaction conditions were as follows: reverse transcription at 50°C for 30 min, 
Taq activation at 95°C for 2 min, and 45 cycles of denaturation at 95°C for 15 s and 
amplification at 55°C for 30 s. Analysis was also performed using the commercial RealStar® 
Influenza RT-PCR Kit 2.0 (Altona Diagnostics, Germany) according to the manufacturer’s 
instructions. The two RT-PCR assays were performed as duplicates in a Bio-Rad CFX96 
system (Bio-Rad Laboratories). 
 
C. Results 
C.1. Optimization of the multiplex RT-SIBA Influenza assay  
 
The multiplex RT-SIBA Influenza assay was optimized for rapid and specific detection of 
influenza A and B virus RNA. Gp32 and UvsX are key components of RT-SIBA. While Gp32 
prevents the formation of secondary structures in the single-stranded DNA (IO and primers), 
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filament complex. This complex catalyzes strand separation of the homologous target 
duplex, which enables primers to bind and extend the target via the action of a polymerase 
(16, 23, 24). The affinity of UvsX for a single-stranded DNA is dependent on the nucleotide 
composition, particularly the ratio of purines to pyrimidines (23). Because the influenza A 
and B assays were designed to detect different target sequences, we reasoned that their 
requirement for UvsX and Gp32 may differ. We sought to determine the optimal 
concentrations of UvsX and Gp32 to efficiently amplify both the influenza A and B virus 
targets in the same reaction tube. 
 
To determine the optimal concentrations of Gp32 and UvsX, the multiplex RT-SIBA Influenza 
assay was conducted using 200–500 ng/ml of each protein. The effects of these various 
concentrations of Gp32 and UvsX on the assay were determined. Figure 1 shows the 
amount of time taken to obtain a positive result with 200 copies of influenza A and B virus 
RNA per reaction. A positive result was obtained when the fluorescence signal of the probe 
exceeded the background signal. The amount of time taken to obtain a positive result for 
influenza A H1N1 decreased as the concentration of UvsX increased from 200 to 500 ng/ml, 
but increased as the concentration of Gp32 increased from 200 to 500 ng/ml. Similar 
findings were made with respect to the amount of time taken to obtain a positive result for 
influenza A H3N2. This is not surprising because the same primers and IO were used to 
detect these two strains. Variation of the UvsX concentration had less of an effect on the 
detection of influenza B virus. By contrast, an increase in the Gp32 concentration 
significantly decreased the amount of time taken to obtain a positive result for influenza B 
virus, opposite to its effect on the detection of influenza A virus. Influenza B virus was not 
detected in reactions containing 200 ng/ml Gp32 and 500 ng/ml UvsX. The difference in the 
amount of time taken to detect influenza A and B viruses could be due to a difference in the 
affinity of UvsX for DNA nucleotides. Based on these findings, subsequent experiments were 
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C.2. Analytical sensitivity of the multiplex RT-SIBA Influenza assay  
 
The analytical sensitivity of the multiplex RT-SIBA Influenza assay was determined using 
RNA extracted from influenza A H1N1, influenza A H3N2, and influenza B viral particles of 
known viral loads (CEID50) and RNA copy numbers. The sensitivity of the assay was 
determined in three independent experiments by adding serial dilutions of RNA extracted 
from viral particles with a CEID50 of 10
6 to one per reaction. Four replicates of each dilution 
were used and the results are shown in Figure 2. The multiplex RT-SIBA Influenza assay 
reproducibly detected all influenza virus strains tested within 20 min using 10 CEID50 per 
reaction. When CEID50 was higher than 100 per reaction, it took as little as 7 min to obtain a 
positive result. These results demonstrate that the multiplex RT-SIBA Influenza assay is 
faster than most RT-PCR methods previously reported to detect influenza viruses. The limit 
of detections (LODs) at which influenza viruses were detected 95% of the time were further 
determined by Probit regression analysis. The LODs of the RT-SIBA Influenza assay for 
influenza A H1N1, influenza A H3N2, and influenza B viruses were 5, 1, and 9 CEID50 per 
reaction, respectively (Table 2), which correspond to 5, 10, and 19 RNA copies per reaction, 
respectively. 
 
C.3. Analytical specificity of the multiplex RT-SIBA Influenza assay 
 
Melting curve analysis was performed to analyze the specificity of the multiplex RT-SIBA 
Influenza assay. A single specific amplicon was observed with influenza A and B virus 
templates (Figure 2d). This suggests that the assay can detect and differentiate between 
influenza A and B viruses. The analytical specificity of the multiplex RT-SIBA Influenza 
assay was further elucidated by including nucleic acids extracted from 16 common 
respiratory pathogens (Table 3). Nucleic acids were extracted from microbes at 
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with the multiplex RT-SIBA Influenza assay. Furthermore, the assay could efficiently detect 





C.4. Evaluation of the multiplex RT-SIBA Influenza assay using NP swab and 
aspirate specimens 
 
The ability of the RT-SIBA Influenza assay to detect influenza viruses was further evaluated 
using 132 retrospective NP swab and aspirate specimens. A total of 44, 40, and 48 of these 
specimens were determined to be positive for influenza A virus, positive for influenza B virus, 
and negative for influenza viruses, respectively. These specimens were re-analyzed using 
the RT-SIBA Influenza assay and two established RT-PCR multiplex influenza assays. The 
results were compared with the previous data (Table 4), and the sensitivity and specificity of 
each assay for the detection of influenza A and/or B viruses were determined. By 
comparison with the previous results, the sensitivities and specificities to detect influenza 
A/B viruses were calculated to be 98.8% (95% CI: 93.6–99.8%) and 100% (95% CI: 92.6–
100%) for the RT-SIBA Influenza assay, respectively; 100% (95% CI: 95.6–100%) and 100% 
(95% CI: 92.6–100%) for the RealStar® Influenza RT-PCR assay, respectively; and 89.3% 
(95% CI: 80.9–94.3%) and 100% (95% CI: 92.6–100%) for the CDC Influenza RT-PCR 
assay, respectively. The CDC Influenza RT-PCR assay had the lowest sensitivity, while the 
sensitivity of the RealStar® Influenza RT-PCR assay was slightly higher than that of the RT-
SIBA Influenza assay.  
 
The sensitivities of the RT-SIBA Influenza, RealStar® Influenza RT-PCR, and CDC Influenza 
RT-PCR assays were 100%, 100%, and 95.5% for the detection of influenza A virus alone, 
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respectively. Moreover, the specificities of the RT-SIBA Influenza, RealStar® Influenza RT-
PCR, and CDC Influenza RT-PCR assays for the detection of influenza virus A alone were 
98.9%, 100%, and 100%, respectively. The specificities of the RT-SIBA Influenza, RealStar® 
Influenza RT-PCR, and CDC Influenza RT-PCR assays for the detection of influenza virus B 
alone were 100%, 96.7%, and 100%, respectively.  
 
The RT-SIBA Influenza assay simultaneously detected influenza A and B viruses in a clinical 
specimen previously reported to be only positive for influenza B virus. In addition, the 
RealStar® Influenza RT-PCR assay simultaneously detected influenza A and B viruses in 
one clinical specimens previously reported to be only positive for influenza A virus. The 
detection of both viruses in these specimens was presumed to be a false positive result 
since it differed from the results from the sending laboratory. Alternatively, these 
discrepancies could reflect the superior sensitivity of the RT-SIBA and RealStar® Influenza 
RT-PCR assays over the CDC Influenza RT-PCR assay and the previously used method. 
These data demonstrate that the RT-SIBA Influenza assay had high analytical sensitivity and 
specificity for the detection of influenza A and B viruses. Furthermore, it took significantly 
less time to obtain a positive result with the RT-SIBA Influenza assay (less than 20 min) than 
with either of the RT-PCR assays (more than 90 min; Ct, ~25). 
 
 
D. Discussion  
 
Timely diagnosis of influenza virus infection is important to manage patients, control 
infection, and prevent the inappropriate use of antibiotics (8, 9). Molecular methods, such as 
isothermal nucleic acid amplification, offer significant advantages such as relatively short 
TATs and simple setups. However, most isothermal amplification methods have mainly been 
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capability (13-15). This has hampered the adoption of such methods in clinical settings, 
especially for the diagnosis of influenza, which requires the detection and differentiation of 
influenza A and B viruses. We previously reported an isothermal method to detect influenza 
A and B viruses in two different reaction chambers (25). In the present study, we developed 
and evaluated an isothermal nucleic acid amplification method called RT-SIBA for the rapid 
detection and differentiation of influenza A and B viruses in a single reaction tube. This 
assay relies on a recombinase-coated oligonucleotide, a reverse transcription enzyme, and 
target-specific primers to exponentially amplify the target sequence of viral RNA (16, 18, 20). 
The reactions are performed at a low and constant temperature (43°C), and therefore do not 
require complex instrumentation.  
 
The multiplex RT-SIBA Influenza assay displayed high analytical sensitivity and specificity 
for the detection of influenza A and B viruses. Moreover, this assay detected 100 copies of 
influenza A H1N1, influenza A H3N2, and influenza B viral RNA within 15 min. This is 
significantly faster than most nucleic acid amplification methods, which take more than 1 h to 
detect such a low number of RNA copies. Furthermore, the RT-SIBA Influenza assay did not 
detect other common respiratory pathogens, suggesting that it is highly specific. The 
concentrations of UvsX and Gp32 proteins and the UvsX:Gp32 ratio can affect the sensitivity 
and speed of RT-SIBA, especially in the case of a multiplex assay. This was true for the 
multiplex RT-SIBA Influenza assay, in which the optimal concentrations of UvsX and Gp32 
differed for the detection of influenza A virus versus influenza B virus. This is likely because 
the affinity of UvsX for an oligonucleotide is dependent on the length and nucleotide 
composition (23, 24). Although both UvsX and Gp32 are crucial for SIBA amplification, they 
also compete with themselves for binding to oligonucleotides (16, 23, 24). Therefore, the 
optimal concentrations of UvsX and Gp32 required for SIBA amplification may differ between 
target regions. Consequently, it is crucial to empirically determine the optimal concentrations 















Page 13 of 23 
 
 
The analytical performance of the multiplex RT-SIBA Influenza assay was further elucidated 
by testing 132 retrospective NP swab and aspirate specimens that were previously 
determined to be positive or negative for influenza viruses. Moreover, the performance of 
this assay for the detection of influenza A and B viruses was compared with those of two 
established RT-PCR assays. The sensitivity of the RT-SIBA Influenza assay (98.8%) was 
significantly better than that of the CDC Influenza RT-PCR assay (89.3%), but slightly lower 
than that of the RealStar® Influenza RT-PCR assay (100%). The specificities of all three 
assays were 100%. Meanwhile, the sensitivities of the RT-SIBA Influenza assay for the 
detection of influenza A and B viruses were 100% and 97.5%, respectively. This slightly 
reduced sensitivity suggests that further optimization is required. Indeed, the assay was 
markedly improved by optimization of the Gp32 and UvsX concentrations. Nonetheless, the 
RT-SIBA Influenza assay displayed a high sensitivity and specificity for the detection of 
influenza A and B viruses and its findings correlated well with those of the reference 
methods. Furthermore, the average amount of time taken to obtain a positive result was 
significantly shorter with the RT-SIBA Influenza assay (<20 min) than with the CDC and 
RealStar® Influenza RT-PCR assays (>90 min). Moreover, the RT-SIBA Influenza assay is 
performed at a low and constant temperature, and can therefore be run using battery-
operated, portable devices with a small footprint. Thus, this assay has potential applications 
in both laboratory and near-patient settings. 
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Table 1 Oligonucleotides used in the multiplex RT-SIBA Influenza assay 
  
Name Sequence 5' --> 3' 
FluA-F primer AATTGATGGCCATCCGAAT 
FluA-R primer AACGGGACT CTAGCAT 
FluA-IO CCCCCCCCCT GAATTCTTTTGGTCGCTGTCTGGCTGTCA mGmUmAmAmGmUmAmUmGmC 
FluA-probe /56-ROXN/AA+A+CGG+GA+CT+C+T/3IABkFQ/ 
FluB-F primer AGATGTTGAATAGCATT 
FluB-R primer AGGCCAAAAACACAATG 
FluB-IO CCCCCCCCCCCCCC TTGCTGGTTGTAATTCAGGATCTTCACTA mAmAmUmUmCmUmGmCmCmA 
FluB-probe /cy5/A+GG+CC+AA+A+AA+C+A/3IAbRQSp 
For invasion oligonucleotides (IOs), bold sequences denote non-homologous seeding area sequences. mA, mC, mG, and 
mU denote 2'-O-methyl RNA nucleotides. F, forward; R, reverse; +, locked nucleic acid bases; IABkFQ, Iowa Black FQ 
quencher; IAbRQSp, Iowa Black RQ quencher; FluA, Influenza A; FluB, Influenza B; RT-SIBA, reverse transcription strand 
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Table 2 Limit of detection of the multiplex RT-SIBA Influenza assay 
 















ATCC VR-95 H1N1 5 5 
Influenza A 
virus 
ATCC VR-544 H3N2 1 10 
Influenza B 
virus 
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Table 3 Potential cross-reactive organisms in the multiplex RT-SIBA Influenza 
assay 
 
Strains Multiplex RT-SIBA Influenza result 
(min) 
Influenza A virus ATCC VR-95 10 
Influenza A virus ATCC VR-544 10 
Influenza B virus ATCC VR-1804 11 
Escherichia coli ATCC 25922 ND* 
Klebsiella pneumonia ATCC 13883 ND* 
Staphylococcus aureus ATCC 6538 ND* 
Staphylococcus epidermidis 2954 ND* 
Streptococcus agalactiae ATCC 12386 ND* 
Streptococcus dysgalactiae ATCC 12388 ND* 
Streptococcus pneumoniae ATCC 6305 ND* 
Streptococcus pyogenes ATCC 19615 ND* 
Parainfluenza virus 1 ATCC - VR-94 ND* 
Coronavirus ATCC-VR-740 ND* 
Adenovirus 1 ATCC VR-1 ND* 
Adenovirus 7 ATCC VR-7 ND* 
Enterovirus 71 ATCC VR-1432 ND* 
Rhinovirus 17 ATCC VR-1663 ND* 
Human respiratory syncytial virus A ATCC VR-1540 ND* 
Human respiratory syncytial virus B ATCC VR-1400 ND* 
 
 
ND* = Not detection through the time of performing the reaction. Nucleic acids were extracted 
from microbes at concentration higher than 10
6
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Table 4 Clinical performance of the multiplex RT-SIBA Influenza assay in 





Influenza A/B virus Influenza A virus Influenza B virus 
Positive Negative Positive Negative Positive Negative 
Positive 83 1 44 0 40 1 
Negative 0 48 1 87 0 91 
Total no. of samples 132 132 132 
Sensitivity (95% CI) 98.8% (93.6–
99.8%) 
100% (92.0–100%) 97.6% (87.4–
99.6%) 
Specificity (95% CI) 100% (92.6–100%) 98.9% (93.8–
99.8%) 
100% (95.6–100%) 
Average detection time 
(minutes) 




RealStar® Influenza RT-PCR (Altona) 
Influenza A/B virus Influenza A virus Influenza B virus 
Positive Negative Positive Negative Positive Negative 
Positive 84 0 44 0 41 0 
Negative 0 48 0 88 1 90 
Total no. of samples 132 132 132 
Sensitivity (95% CI) 100% (95.6–100%) 100% (92.0–100%) 100% (91.4–100%) 
Specificity (95% CI) 100% (92.6–100%) 100% (95.9–100%) 96.7% (94.0–
99.8%) 
Average detection time 
(Ct) 




CDC Influenza RT-PCR 
Influenza A/B virus Influenza A virus Influenza B virus 
Positive Negative Positive Negative Positive Negative 
Positive 75 9 42 2 33 8 
Negative 0 48 0 88 0 91 
Total no. of samples 132 132 132 






Specificity (95% CI) 100% (92.6–100%) 100% (95.8–100%) 100% (96.0–100%) 
Average detection time 
(Ct) 





















Figure 1. Optimization of the multiplex RT-SIBA Influenza assay. Impact of the concentrations of 
Gp32 and UvsX on the detection of influenza A and B viruses. Influenza B virus was not detected in 
reactions containing 200 ng/ml Gp32 and 500 ng/ml UvsX 
 
 
Figure 2. Sensitivity of the multiplex RT-SIBA Influenza assay for the detection of influenza viruses. 
(a) Influenza A H1N1 virus. (b) Influenza A H3N2 virus. (c) Influenza B virus. (d) Melting curve profiles 
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Highlights:  
 We present preliminary clinical evaluation of a novel molecular diagnostic platform for 
the diagnosis of RSV 
 The method displayed high level of sensitivity and specificity and correlated well with 
those of the reference methods 
 The method detected RSV within 15 minutes and can potentially be used in near 
patient or field setting. 
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